# ImmuPharma PLC Positive results of P140

- Link: https://www.directorstalkinterviews.com/immupharma-plc-positive-results-p140/412752840
- Published: 2018-06-14T07:17:20+01:00
- Author: Giles Arbor

**ImmuPharma PLC** (LON:IMM), the specialist drug discovery and development company,
has today provided insight into its positive results from pre-clinical studies of
the P140 peptide for Chronic Inflammatory Demyelinating Polyneuropathy (‘CIDP’),
a relapsing-remitting autoimmune-mediated inflammatory disease of the peripheral
nervous system for which specifically-targeted therapies are still lacking.

The results have been published in the ‘Journal of Autoimmunity’ entitled: “An autophagy-
targeting peptide to treat chronic inflammatory demyelinating polyneuropathies”.
This paper is available to review on line at the Journal of Autoimmunity: [https://doi.org/10.1016/j.jaut.2018.05.009](https://doi.org/10.1016/j.jaut.2018.05.009)

This study was headed by Professor Sylviane Muller, inventor of P140/Lupuzor™, ImmuPharma’s
lead compound for Lupus, a potentially life threatening auto-immune disease.

It has already been demonstrated by a number of presentations by ImmuPharma PLC 
that the mechanism of action of P140/Lupuzor™ can potentially be applied to a number
of other auto-immune diseases in addition to Lupus.

Key highlights of the CIDP pre-clinical study include:

· Macro-autophagy and chaperone-mediated autophagy (CMA), are significantly altered
in non-neuronal cells of the peripheral nervous system

· P140/Lupuzor™, known to target CMA and successfully used in pathological settings
where CMA markers are overexpressed, considerably ameliorated the clinical and biological
course of the disease in the CIDP model used

· P140 displayed prophylactic and therapeutic effects, both in terms of disease 
intensity and chronicity, and preserved sciatic nerves from disease-related damages

· The findings uncover new disrupted molecular pathways in the model and provide
a proof-of-concept that targeting CMA might represent a promising therapeutic strategy
for treating inflammatory neuropathies for which no disease-specific treatment is
currently available.

> **Commenting on this announcement, Professor Sylviane Muller said:** “Over the
> last couple of years we have provided further evidence of the role the P140 peptide
> can take in the potential treatment of other autoimmune diseases in addition to
> Lupus. We are delighted that these results demonstrate positive pre-clinical data
> in a murine model of CIDP, which has no available disease-specific treatment. 
> We look forward to providing a further update on the progress of our CIDP programme
> in due course.”

Share on:
